PTPL1 is a non-receptor protein tyrosine phosphatase involved in apoptosis regulation, although controversial findings have been reported in different cancer types. We report here a proapoptotic role for PTPL1 in PC3 and LNCaP prostate cancer cells, as its absence induces apoptosis resistance upon treatment with different drugs. In PC3 cells, PTPL1 silencing by small interfering RNA influences the expression levels of Bcl-xL and Mcl-1 S proteins as well as final events in the apoptotic process such as activation of caspases and caspase-mediated cleavage of proteins like Mcl-1 or poly (ADP-ribose) polymerase. We have identified PKCd as an intermediary of PTPL1-mediated apoptotic signalling and that phosphorylation status of NF-jB and IjBa is influenced by PTPL1 and PKCd. Furthermore, the loss of PTPL1 and PKCd expression in poorly differentiated, more aggressive human prostate cancers also indicate that their absence could be related to apoptosis resistance and tumour progression. Prostate cancer is one of the most frequently diagnosed cancers. Castration therapy remains the most widely used treatment for locally advanced prostate cancer and although initially effective, after months to few years this therapy fails, leading to a lethal hormone-refractory disease.
PTPL1 is a non-receptor protein tyrosine phosphatase involved in apoptosis regulation, although controversial findings have been reported in different cancer types. We report here a proapoptotic role for PTPL1 in PC3 and LNCaP prostate cancer cells, as its absence induces apoptosis resistance upon treatment with different drugs. In PC3 cells, PTPL1 silencing by small interfering RNA influences the expression levels of Bcl-xL and Mcl-1 S proteins as well as final events in the apoptotic process such as activation of caspases and caspase-mediated cleavage of proteins like Mcl-1 or poly (ADP-ribose) polymerase. We have identified PKCd as an intermediary of PTPL1-mediated apoptotic signalling and that phosphorylation status of NF-jB and IjBa is influenced by PTPL1 and PKCd. Furthermore, the loss of PTPL1 and PKCd expression in poorly differentiated, more aggressive human prostate cancers also indicate that their absence could be related to apoptosis resistance and tumour progression. Prostate cancer is one of the most frequently diagnosed cancers. Castration therapy remains the most widely used treatment for locally advanced prostate cancer and although initially effective, after months to few years this therapy fails, leading to a lethal hormone-refractory disease. 1 Unfortunately, the mechanisms underlying resistance of castrationresistant prostate cancer cells to chemotherapy-mediated apoptosis are still unknown. Two main pathways of apoptosis in mammalian cells are the death receptor and the mitochondrial pathways. In type I cells, engagement of Fas receptor either by Fas ligand or by antibody cross-linking induces the formation of a death-inducing signalling complex (DISC) that leads to activation of caspase 8 . The activation of downstream caspases by the DISC is sufficient for the execution of Fasinduced apoptosis. 2 In type II cells, such as PC3 prostate cancer cells, 3 there is reduced DISC formation and Bcl-2 or Bcl-xL protect against Fas-mediated apoptosis. 2 Thus, depending on the cell type, Fas-mediated apoptosis can be dependent or independent on the mitochondrial pathway.
Protein tyrosine phosphatase L1 (PTPL1, also known as PTPN13, FAP-1, PTP-BAS or hPTP1E) is a non-receptor protein tyrosine phosphatase whose role in apoptosis is a matter of debate. Several groups have addressed an antiapoptotic role for PTPL1 in different cell lines, mainly by inhibition of Fas-mediated apoptosis, while others have demonstrated a proapoptotic function. 4 Studies in HeLa, HEK293 cells, and breast cancer cells showed that PTPL1
dephosphorylates IRS-1 and induces apoptosis at least by inhibition of the IGF-IR/IRS-1/PI3K/Akt pathway. 5, 6 In SW480 colon cancer cells, PTPL1 overexpression increases susceptibility to Fas-mediated apoptosis. 7 Data regarding PTPL1 function in prostate cancer cells are still lacking. Phenylethyl isothiocyanate (PEITC) is present in cruciferous vegetables 8 and several studies have indicated that it can inhibit prostate cancer cell growth in vitro and in vivo, and induce apoptosis. [9] [10] [11] PEITC-induced apoptosis has been correlated with changes in the protein levels of Bcl-2 family proteins in PC3 and TRAMPderived cells. 9, 11, 12 Especially, ectopic expression of Bcl-xL in PC3 cells has been shown to confer partial protection against PEITC-induced apoptosis. 11 It has also been proposed that PEITC inhibits IkBa phosphorylation and its subsequent degradation and the nuclear translocation of the p65 subunit of NF-kB in PC3 cells stably transfected with an NF-kB-luciferase reporter construct. 13 Thus, we sought to investigate in prostate cancer cells the apoptotic effect of PEITC and anti-Fas antibody either alone or in combination, the influence of PTPL1 in the apoptosis induced by these stimuli and the signalling pathways involved in the process.
Results

PEITC sensitizes PC3 cells to anti-Fas induced apoptosis.
As previously established, [10] [11] [12] PC3 cells are sensitive to PEITC-mediated apoptosis and our experiments also confirm this issue (Figure 1 ). Data regarding anti-Fas sensitivity of PC3 cells are more controversial, [14] [15] [16] but they were relatively sensitive to anti-Fas treatment, as it produces a slight induction of apoptosis. However, when cells were pre-treated with PEITC for 1 h and then anti-Fas antibody was added, we observed a significantly more extensive apoptosis than with either PEITC or anti-Fas alone. poly (ADP-ribose) polymerase (PARP) and caspase-7 cleavage were clearly more pronounced in PC3 cells treated with PEITC and anti-Fas in combination, followed by cells treated with PEITC alone and then by cells treated with anti-Fas alone (Figure 1) . Thus, simultaneous treatment with PEITC and anti-Fas causes a more extensive apoptosis in PC3 cells than any of the drugs separately.
PTPL1 silencing abrogates apoptosis induction in PC3 cells. We sought to investigate the influence of PTPL1 expression on the sensitivity to apoptosis of PC3 cells. Figure 2a shows knockdown of endogenous PTPL1 by small interfering RNA (siRNA), at both the mRNA and protein levels. As observed by PARP cleavage (Figure 2b ), PC3 cells silenced for PTPL1 showed less sensitivity to apoptosis than siRNA control cells. The effect was seen either with PEITC or anti-Fas alone or with both drugs but again it was more striking when PEITC and anti-Fas were used in combination. Then, several proteins involved in apoptosis were examined (Figure 2c ). Caspases 3, 7, and 9 were more 
Signal transduction regulated by PTPL1 involves PKCd.
Following an initial screening of kinases (data not shown), we focus on protein kinase C delta (PKCd) and a diminished PKCd phosphorylation was detected at T505 (located within the activation loop of the kinase) in cells with endogenous PTPL1 treated with PEITC and anti-Fas, undergoing apoptosis. On the contrary, cells silenced for PTPL1 treated in the same way, with impaired apoptosis, sustained the basal level of PKCd T505 phosphorylation. The decrease in the phosphorylation of PKCd at T505 occurs in PC3 cells expressing endogenous PTPL1 treated with PEITC and antiFas, PEITC or paclitaxel and was not primarily due to downregulation of PKCd expression (Figures 4a and b) . As reported, PKCd is a functional kinase even without T505 phosphorylation 17, 18 and to study more profoundly the involvement of PTPL1-dependent PKCd regulation in (Figure 5a ). These data were confirmed by diminished cleavage of PARP and caspases 3, 7, and 9 in all treated siRNA conditions (Figure 5b) . Thus, interestingly, PKCd siRNA, in the same way as PTPL1 silencing, induces apoptosis resistance upon treatment; moreover, simultaneous PTPL1 and PKCd silencing, produces greater resistance to apoptosis than either PTPL1 or PKCd silencing alone. To further confirm the apoptosis resistance obtained in siRNA PKCd cells treated with PEITC and anti-Fas, PC3 cells were silenced with PKCd siRNA and treated with PEITC alone or paclitaxel. Annexin V binding/PI assays showed decreased apoptosis upon PKCd silencing after treatment with both drugs (Supplementary Figure S1) .
It has been reported that a mutant PKCd unable to become phosphorylated in the activation loop lacks the capacity to induce NF-kB reporter activation, 18 so the activation status of NF-kB was determined, measured by the phosphorylation of S276 of the p65 subunit, a phosphorylation known to be important for optimal transactivation activity of NF-kB. 19 Cells silenced for PKCd or both PTPL1 and PKCd maintain, approximately, the same level of NF-kB S276 phosphorylation either in untreated or in PEITC and anti-Fas-treated cells, whereas its phosphorylation level shows a slight decrease in treated PTPL1-silenced cells and is pronouncedly diminished in treated cells expressing endogenous PTPL1 and PKCd. Total level of NF-kB protein remains unaffected (Figure 5b ). To test whether these changes in the activation status of NF-kB after PEITC and anti-Fas treatment were accompanied by changes in the subcellular distribution of the protein, an immunofluorescence assay was performed (Supplementary Figure S2) . PEITC and anti-Fas treated siRNA control cells shows cytosolic staining, whereas treated siRNA PTPL1 and siRNA PKCd cells show a redistribution of the protein from cytosol to the nucleus, according to the higher activation of NF-kB found in these conditions in relation to siRNA control cells.
Then, we focused on IkBa, another regulator of NF-kB activity. IkBa serine phosphorylation on residues 32 and 36 results in its proteolytic degradation and NF-kB activation. 20 Figure 5b shows that IkBa phosphorylation on S32 and S36 presents the major decrease in PC3 cells expressing endogenous PTPL1 and PKCd treated with PEITC and antiFas, whereas dephosphorylation is impaired in treated cells silenced for PKCd, PTPL1, or both PTPL1 and PKCd. IkBa phosphorylation at Y42 also leads to IkBa dissociation from NF-kB, 20 so its phosphorylation level was also assessed. Y42 phosphorylated IkBa also shows a major decrease in treated cells expressing PTPL1 and PKCd than in any other condition tested. IkBa total level does not show noticeable changes.
Finally, Akt phosphorylation status was also addressed in this setting. There was a noticeable diminishing of Akt phosphorylation on S473 in PC3 cells silenced for PTPL1, but the treatment with PEITC and anti-Fas induced a decrease in Akt phosphorylation irrespective of the presence or absence of PTPL1 or PKCd (Figure 5b ). PKCd-transfected PC3 cells treated in the same way also showed more PARP cleavage than empty vector-transfected cells (Figure 6b ) (Po0.05). NF-kB phosphorylation was almost undetectable in treated PTPL1 or PKCd-transfected Figure S3) . PTPL1 or PKCd silencing induces apoptosis resistance in LNCaP cells. To ascertain whether these findings could be extended to another prostate cancer cell line, PTPL1 and PKCd were downregulated by siRNA in LNCaP cells. Silenced cells were then treated with PEITC and anti-Fas and apoptosis induction was assessed by PARP cleavage (Figure 7 ). PTPL1-silenced LNCaP cells were more resistant to apoptosis induction than siRNA control cells, with differences in PARP cleavage being statistically significant (Po0.05) (Figure 7a ). LNCaP cells silenced for PKCd also showed apoptosis resistance after treatment (Po0.05) ( Figure 7b ). Next, we examined NF-kB activation status in this setting to test whether PTPL1 and PKCd influence NF-kB signalling. NF-kB phosphorylation was diminished in both treated siRNA PTPL1 and PKCd cells, in a similar way as treated siRNA control cells ( Figure 7b) ; thus, PTPL1 and PKCd do not seem to influence NF-kB phosphorylation in this cell line. Then, the same experimental approach but using paclitaxel was performed. Both paclitaxel-treated PTPL1 and PKCd silenced cells show diminished PARP cleavage, as compared with treated siRNA control cells (Supplementary Figure S4 ), but differences were only statistically significant in the case of siRNA PKCd cells (Po0.05).
PTPL1 and PKCd immunohistochemical expression in prostate cancer tissues. We performed an immunohistochemical analysis of PTPL1 and PKCd expression in 76 prostate cancer biopsies (Figure 8) . Tumour glands showed different degrees of cytoplasmic immunostaining for PTPL1. Well-differentiated, low Gleason score tumours showed strong PTPL1 positivity, whereas poorly differentiated, high Gleason score tumours were either weakly or not immunostained. Statistical analysis showed a significant association (Po0.05) between PTPL1 immunohistochemical expression and Gleason score. Immunostaining for PKCd showed a similar pattern as well-differentiated, low Gleason score tumours showed significantly higher levels of PKCd expression than poorly differentiated, high Gleason score tumours (Po0.01). 
Discussion
Several studies have demonstrated that different compounds can sensitize prostate cancer cells to Fas-induced apoptosis. 15, 21, 22 In the case of PEITC, a sensitizing effect on Fasmediated apoptosis has been reported in T24 bladder cancer cells and in Jurkat cells overexpressing Bcl-2. 23 We have observed that the treatment with PEITC also sensitizes PC3 cells to anti-Fas induced apoptosis and that the extent of apoptosis caused by this treatment was higher than that achieved with any of the compounds alone. Protein tyrosine phosphorylation is a major regulator of signal transduction in higher eukaryotes. 4 PTPL1 is the largest non-receptor protein tyrosine phosphatase and its function in apoptosis regulation is a matter of debate. There is some evidence suggesting that PTPL1 may act as a negative regulator of apoptosis and as a tumour promoting gene, while other studies point towards a role for PTPL1 as a positive regulator of apoptosis and as a tumour suppressor. 4 Specifically in prostate cancer, two studies concerning sensitivity to Fas-mediated apoptosis of prostate cancer cell lines failed to find a correlation between resistance to Fas-mediated apoptosis and increased expression of PTPL1 at the mRNA level, 15, 16 but functional studies are lacking in prostate cancer addressing the role of PTPL1 in apoptosis. In this study, we have determined a proapoptotic role for PTPL1 in PC3 prostate cancer cells, as its overexpression promotes apoptosis in cells treated with PEITC and anti-Fas simultaneously or paclitaxel and its downregulation induces apoptosis resistance upon treatment with these agents. Interestingly, PTPL1 silencing is also associated with diminished apoptosis in LNCaP cells treated with PEITC and anti-Fas.
In the case of siRNA control and siRNA PTPL1 PC3 cells treated with PEITC and anti-Fas, changes in Bcl-2 family proteins were a slight induction of Bcl-xL in PTPL1 silenced cells and an increase in proapoptotic Mcl-1 S and in the 24-kDa cleaved fragment of Mcl-1 L in siRNA control-treated cells. It has been suggested that caspase-cleaved fragment(s) of Mcl-1 lose anti-apoptotic potential and become proapoptotic or alternatively, that Mcl-1 cleavage may disrupt the protective function of the protein. 24 Taken together, these results suggest that a PTPL1-mediated signalling pathway could influence the expression levels of Bcl-xL and Mcl-1 S proteins as well as final events in the apoptotic process such as activation of caspases and subsequently, caspase-mediated cleavage of proteins like Mcl-1 or PARP.
PKC family of serine/threonine kinases is activated by diverse stimuli and participates in many cellular processes. Most studies indicate that PKCd isoform is involved in suppression of cell proliferation and induction of apoptosis, but there are a few studies pointing to a role of PKCd in cell survival and anti-apoptotic responses. 25 In relation to prostate cancer, some studies point towards a role of PKCd in migration and invasion, 26, 27 while others have reported that expression of PKCd is required in anticancer drugs or death receptor-induced apoptosis. [28] [29] [30] In this sense, we have observed that PKCd overexpression increases the apoptosis induction by PEITC and anti-Fas or paclitaxel in PC3 cells. It has been established that PKCd mediates paclitaxel, etoposide 29 or phorbol ester-induced apoptosis in LNCaP cells; 30 according to these data, PKCd silencing induces apoptosis resistance upon treatment with PEITC and anti-Fas or paclitaxel in LNCaP cells. We conclude that PKCd and PTPL1 seem to exert a proapoptotic function in both androgensensitive LNCaP cells and androgen-resistant PC3 cells, although the signalling events involved in the apoptotic process differ between both cell lines. PKCd activity is regulated by binding of cofactors to the regulatory region and by phosphorylation on its kinase domain, especially on its activation loop, but the dependence of PKCd activity on its activation loop phosphorylation is still controversial. 17 Interestingly, a study has shown that a mutant activation loop non-phosphorylated PKCd is catalytically active in cells, but its pattern of substrate phosphorylation and function is markedly changed. Notably, this mutant PKCd is as active as wild-type PKCd in induction of apoptosis. 18 We have observed that in PC3 cells expressing endogenous PTPL1, PKCd phosphorylation at T505 (located within the activation loop) is clearly diminished upon treatment with PEITC and anti-Fas, whereas treated cells silenced for PTPL1 sustain the basal level of PKCd phosphorylation. It was confirmed as well that the loss of PKCd T505 phosphorylation in the presence of PTPL1 also occurs when PEITC or paclitaxel is used to induce apoptosis. It is interesting to note that the loss of PKCd T505 phosphorylation only occurs in cells undergoing apoptosis, so the question arises whether the loss of phosphorylation means a loss of activity of the kinase and resembles a loss of the protein, or if the presence of T505 dephosphorylated PKCd via PTPL1 is relevant for the induction of apoptosis. The latter question was confirmed, since the silencing of PKCd by siRNA induces apoptosis resistance in PC3 cells. Furthermore, the simultaneous silencing of PTPL1 and PKCd causes even a greater apoptosis resistance than any of them separately, supporting the notion that the presence of both proteins is necessary for a better efficiency of the apoptotic process. Thus, we have shown that PC3 cells are more sensitive to apoptosis induction by PEITC and anti-Fas in the presence of both PKCd and PTPL1, that PKCd is primarily unphosphorylated at T505 in cells undergoing apoptosis triggered by diverse stimuli and that the loss of T505 phosphorylation of PKCd may be mediated, probably indirectly, by PTPL1. As mentioned above, a mutant PKCd lacking activation loop phosphorylation has been reported to be as active as wild-type PKCd in the induction of apoptosis but displays a substrate-selective defect in phosphorylation when co-targeted with substrates in the cell and it is defective in activity in AP-1 and NF-kB reporter assays that require kinase activity. 18 NF-kB mediates mainly anti-apoptotic signals in prostate cancer, 31 so we investigated its activation status. Treatment of PC3 cells with PEITC and anti-Fas has hardly any effect on NF-kB phosphorylation when PKCd or both PTPL1 and PKCd are silenced. However, in treated cells expressing endogenous PTPL1 and PKCd, in which PKCd is primarily unphosphorylated at T505, active NF-kB (phosphorylated) is lower than in treated cells expressing endogenous PKCd but silenced for PTPL1, with PKCd phosphorylated at T505. According to these data, NF-kB dephosphorylation is achieved more efficiently when T505 dephosphorylated PKCd, via PTPL1, is present. Immunofluorescence studies also revealed a nuclear accumulation of NF-kB in PC3 cells silenced for PTPL1 or PKCd treated with PEITC and antiFas, supporting the notion of increased NF-kB activation under these conditions. Moreover, PTPL1 or PKCd overexpression leads to decreased NF-kB activation after PEITC and anti-Fas treatment in PC3 cells, corroborating again the influence of PTPL1 and PKCd in NF-kB signalling. Nonetheless, in the case of LNCaP cells, NF-kB phosphorylation diminishes in PEITC and anti-Fas-treated siRNA PTPL1 and siRNA PKCd cells, thus suggesting the involvement of alternative pathways in PTPL1 and PKCd-mediated signalling in LNCaP cells.
The phosphorylation status of IkBa, a negative regulator of NF-kB activity, was also examined. IkBa phosphorylation on serines 32 and 36 leads to its ubiquitination and degradation, which in turn promotes the translocation of NF-kB from the cytoplasm to the nucleus, where it becomes an active transcription factor. 31 IkBa phosphorylation on tyrosine 42 also induces IkBa dissociation from NF-kB, but without proteolytic degradation 20 and, interestingly, it has been shown that phosphorylated IkBa at Y42 is a substrate of PTPL1 in vitro. 32 We have observed that, in PC3 cells treated with PEITC and anti-Fas expressing endogenous PTPL1 and PKCd, IkBa undergoes extensive dephosphorylation on S32, S36, and Y42. However, when PKCd, PTPL1 or both are silenced, dephosphorylation on the three sites upon drug treatment is impaired. It has been reported that PEITC inhibits IkBa phosphorylation and decreases the nuclear translocation of p65 subunit of NF-kB; 13 thus, based on this previous work and on the above-mentioned results, we propose that inhibition of IkBa degradation and suppression of NF-kB activity (by both IkBa association and dephosphorylation) could be mediated, at least in part, by PTPL1 and PKCd, and that these signalling events contribute to apoptosis in PC3 prostate cancer cells.
Akt is a serine/threonine kinase that promotes cancer cell survival and mediates mainly anti-apoptotic signalling.
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PTPL1 has been shown to inhibit Akt phosphorylation, 6 while others fail to find such a correlation. 7 We have detected diminished Akt basal phosphorylation in PC3 cells silenced for PTPL1; however, Akt phosphorylation levels decrease after treatment either in the presence or in the absence of PTPL1 or PKCd. The ability of PEITC and anti-Fas treatment to downregulate phosphorylated Akt in all conditions tested could indicate that PTPL1 and PKCd are not required to dephosphorylate Akt.
PKCd immunohistochemical expression in prostate cancers is also controversial. A study of 23 prostate cancer specimens reported that PKCd was only expressed by stroma but not by epithelium. 34 However, others have found a high expression of PKCd in the epithelial component of prostate cancers, 26, 27 irrespective of the Gleason score. 26 PTPL1 immunohistochemical expression has not yet been assessed in prostate cancers. We have found in a statistically significant way that immunohistochemical expression of both PTPL1 and PKCd in prostate cancer tissues is higher in well-differentiated, low Gleason score tumours than in poorly differentiated, high Gleason score tumours. In this sense, PTPL1 expression at the mRNA level has been found to be an independent favourable prognostic indicator for overall survival in patients with breast cancer. 35 Loss of these proteins in prostate tumours of less favourable prognosis also indicates that their absence could be related to apoptosis resistance and tumour progression.
Materials and Methods
Cell culture and plasmid transfections. Human prostate cancer PC3 and LNCaP cell lines were obtained from the Interlab Cell Line Collection (Genoa, Italy). All the experiments were done using vials from the first 10 passages after receipt. Cells were routinely grown in RPMI-1640 supplemented with 10% heatinactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 mM HEPES buffer and 1 mM glutamine in a 371C, humidified incubator under 5% CO 2 . Cells were harvested by trypsinization. Transient transfections with pCMV6-XL4-PTPL1 or pCMV6-XL5-PKCd plasmids (Origene, Rockville, MD, USA), were carried out using the FuGENE reagent (Promega, Madison, WI, USA), according to manufacturer's instructions. Cells were subjected to different treatments 24 or 48 h after transfection.
Small interfering RNA. siRNA transfections were carried out using the Dharmafect reagent (Thermo Fisher Dharmacon, Lafayette, CO, USA) according to manufacturer's instructions. The PTPL1-specific siRNA and the control-negative siRNA were from Qiagen (Hilden, Germany). PKCd-specific siRNA was from Thermo Fisher Dharmacon. All siRNAs were used at 100 nM. Cells were subjected to different treatments 24 or 48 h after silencing.
